Effects of L-Ornithine-L-Aspartate on Angiogenesis and Perfusion in Subacute Hind Limb Ischemia: Preliminary Study

• Published in: Biomedicines Vol. 12; no. 8; p. 1787
• Main Authors: Jung, Sanghoon, Park, Ye Jin, Jeon, Jiwon, Kim, Kyuseok
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 06.08.2024; MDPI
• Subjects: Amputation; Angiogenesis; Antibodies; Aspartate; Aspartic acid; Brief Report; Care and treatment; Development and progression; Femoral artery; Health aspects; Heart failure; Immunohistochemistry; Ischemia; L-ornithine-L-aspartate; Limbs; Neovascularization; Nitric oxide; Ornithine; Perfusion; Perfusion (Physiology); peripheral arterial disease; Proteins; Sorbitol; Testing; Vascular endothelial growth factor; Western blotting; South Korea; United States > US; L-ornithine-L-aspartate; angiogenesis; peripheral arterial disease
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines12081787

The current treatment options for peripheral arterial disease (PAD) are limited due to a lack of significant high-level evidence to inform clinical decisions and unfavorable outcomes in terms of cost-effectiveness and amputation rates. In order to suggest the use of the commercially available L-Ornithine-L-Aspartate (LOLA) for treating PAD, we induced hind limb ischemia (HLI) by unilaterally ligating the femoral artery in a rat model. The rats were randomly divided into three groups, with seven rats assigned to each group: group 1 (control), group 2 (sorbitol), and group 3 (LOLA). Intraperitoneal injections were administered five times on post-operative days (PODs) 3, 5, 7, 10, and 12. Perfusion imaging was conducted on PODs 7 and 14 and compared to pre-operative perfusion imaging. Immunohistochemistry staining and Western blotting were performed after the final perfusion imaging. Group 3 showed a significant increase in perfusion, high CD31-positive capillary lumen density, and substantial overexpression of VEGF in the ischemic limb during the subacute phase of HLI. In conclusion, this study provides the first documented evidence of angiogenesis and perfusion recovery in the subacute phase of the HLI model following the administration of LOLA. With LOLA readily available on the commercial market, the implementation of LOLA treatment for PAD in humans can be expedited compared to other therapies still in the developmental stage.